KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBT (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBT for 15 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 107.25% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.0 million through Dec 2025, down 150.1% year-over-year, with the annual reading at -$49.0 million for FY2025, 150.1% down from the prior year.
  • EBT for Q4 2025 was -$1.9 million at Supernus Pharmaceuticals, up from -$58.0 million in the prior quarter.
  • The five-year high for EBT was $44.9 million in Q3 2024, with the low at -$58.0 million in Q3 2025.
  • Average EBT over 5 years is $9.3 million, with a median of $10.4 million recorded in 2021.
  • The sharpest move saw EBT soared 2564.85% in 2024, then crashed 2499.59% in 2025.
  • Over 5 years, EBT stood at $2.1 million in 2021, then soared by 1613.31% to $35.1 million in 2022, then crashed by 97.18% to $990000.0 in 2023, then skyrocketed by 2564.85% to $26.4 million in 2024, then crashed by 107.25% to -$1.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$1.9 million, -$58.0 million, and $16.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.